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RENAL C4D DEPOSITION IS A MARKER OF HEMATOPOIETIC STEM CELL
TRANSPLANT (SCT)-ASSOCIATED THROMBOTIC MICROANGIOPATHY
(TMA)
Laskin, B.L., Goebel, J., Yin, H.J., Luo, G., Khoury, J.C., Davies, S.M.,
Jodele, S. Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
C4d is a marker of classical complement activation by tissue spe-
cific antibodies (abs) or endothelial damage. Currently, peritubular
capillary (PTC) C4d deposition aids in the diagnosis (dx) of ab me-
diated kidney transplant rejection (AMR). An uncontrolled case se-
ries reported PTC and glomerular C4d staining in patients with
SCT-TMA (Mii et al, Path Int 2011). Expanding on these find-
ings, we hypothesized that renal tissue from patients with SCT-
TMA would more frequently show C4d deposition compared to
controls.
Methods: Retrospective analysis of all renal biopsy and autopsy
specimens from pediatric patients undergoing SCT at our institu-
tion. Using histological criteria alone, patients were divided into
TMA and non-TMA (control) groups. C4d staining was performed
by immunohistochemistry on formalin-fixed, paraffin-embedded tis-
sue and was evaluated on arterioles, PTCs, glomeruli, and tubular
basement membranes. Specifically, rabbit anti-human C4d poly-
clonal ab was applied to sections and C4d was independently graded
(diffuse: 50-100%; focal: 5-50%; rare: 1-5%; negative: 0%) by two
pathologists, blinded to each subject’s underlying dx.
Results: 20 total specimens were identified (19 subjects). Of these, 8
specimens (7 subjects) had histologic evidence of TMA (5 biopsy, 3
autopsy). 1 TMA subject had both a biopsy and autopsy with similar
findings, therefore only the autopsy findings are included. The 12
SCT recipient autopsies without TMA served as controls. Diffuse
and focal arteriolar C4d staining was far more common in TMA
specimens compared to controls (71.4% versus 8.3%, p 5 0.01).
PTC C4d staining was present in just under half of TMA samples
and was absent in controls (p 5 0.04). Glomerular C4d staining
was similar in both groups and tubular basement membrane staining
was rare.
Conclusions: This is the first report of arteriolar C4d deposition in
SCT-TMA, implicating localized complement fixation due to as yet
unidentified abs or ab-independent direct endothelial damage in the
pathogenesis of TMA. PTC C4d staining was found only in TMA,
while glomerular staining was non-specific as it was similar in bothTable. C4d Deposition in TMA
Histology proven
TMA (n 5 7) Control (n 5 12) p-value*
Pathology Results
Arteriolar C4d+ 5/7 (71.4%) 1/12 (8.3%) 0.01
PTC C4d+ 3/7 (42.9%) 0/12 (0%) 0.04
Glomerular capillary
C4d+
4/7 (57.1%) 10/12 (83.3%) 0.30
Tubular basement
membrane C4d+
2/7 (28.6%) 0/12 (0%) 0.12
Clinical Results
Age (years) 3.6 (1.7-4.5)
[0.6-4.9]
3.2 (1.4-17.1)
[0.9-28.1]
0.55
Gender (male) 3/7 (42.9%) 8/12 (66.7%) 0.38
Specimen day
post-SCT
237 (43 - 631)
[19 - 2281]
172 (78 - 253)
[9 - 887]
0.50
Malignancy 5/7 (71.4%) 2/12 (16.7%) 0.03
Immunodeficiency 1/7 (14.3%) 9/12 (75.0%) 0.03
Bone marrow failure 1/7 (14.3%) 1/12 (8.3%) 0.03
Allogeneic 2/7 (28.6%) 11/12 (91.7%) 0.01
Autologous 5/7 (71.4%) 1/12 (8.3%) 0.01
GVHD in those at
risk (allogeneic)
1/2 (50%) 3/11 (27.3%) 1.00
Viral infection 4/7 (57.1%) 4/12 (33.3%) 0.38
Dialysis 6/7 (85.7%) 5/12 (41.7%) 0.15
*from Fisher’s exact test for categorical variables and Wilcoxon Rank
sum for continuous variables; data expressed as n (%) or median
(25th-75th percentile) [range].groups. Although the preferential arteriolar C4d staining is incom-
pletely understood, it may identify a renal site of injury, explaining
the dramatic hypertension often seen in TMA. Future research
should assess if patients with SCT-TMA and renal C4d deposition
will benefit from therapies currently used to treat kidney transplant
AMR.
287
NA€ıVE CD19-SPECIFIC T CELLS EXHIBIT SUPERIOR PROLIFERATION AND
POTENTIAL FOR ADOPTIVE IMMUNOTHERAPY
Singh, H.1, Figliola, M.J.1, Dawson, M.J.1, Zhang, L.1, Yang, G.1,
Huls, H.1, Kelly, S.1, Kebriaei, P.2, Champlin, R.E.2, Cooper, L.J.N.1
1U.T.M.D. Anderson Cancer Center, Houston, TX; 2U.T. M.D. Ander-
son Cancer Center, Houston, TX
T cells in human peripheral blood can be characterized as na€ıve
(TN), central memory (TCM) and effector memory (TEM). We and
others seek to define the best cellular substrate for genetic modifica-
tion and expression of tumor-specific immunoreceptors, such as
a CD19-specific chimeric antigen receptor (CAR) for adoptive
transfer in pediatric and adult patients after hematopoietic stem
cell transplantation. Na€ıve-derived effector cells (TEFF[sup]N[/sup])
are an attractive T-cell population for adoptive immunotherapy as
they confer improved anti-tumor activity in a mouse (pmel-1 tumor)
model. Therefore, we determined the relative frequency of TN
(CD62L+CD45RAneg), TCM (CD62L
+CD45RAneg), TEM
(CD62LnegCD45RAneg) and TEMRA (CD62L
negCD45RA+) subsets
in peripheral blood mononuclear cells (PBMC) from normal
healthy donors (n 5 21) and observed an abundance of circulating
TN cells compared toTCM (p\0.001), andTEM (p\0.05). To deter-
mine if we could retrieve CAR+ TEFF[sup]N[/sup] and propagate them
ex vivo to clinically-appealing numbers, PBMC were sorted into
three T-cell subsets and genetically modified by electroporation
to express a CD19-specific CAR using the Sleeping Beauty (SB)
DNA plasmid system. Our artificial antigen presenting cells
(aAPC) were then used to numerically expand CD19-specific T cells
in a CAR-dependent manner.We observedCD19-specific T cells in
all subsets, with total cell numbers higher in TEFF[sup]N[/sup] than
TEFF[sup]CM[/sup] or TEFF[sup]EM[/sup]. These increased cell numbers
were explained by the enhanced proliferative capacity of TEFF[sup]N
[/sup]. Although specific cytolytic ability was diminished for CAR
+
TEFF[sup]N[/sup], in contrast to the other T-cell subsets, they secreted
more IFN-g in response to CD19. These data suggest that TN in
PBMC can be selectively electroporated and propagated using our
current platforms (SB and aAPC system) for generating clinical-
grade CAR+ T cells.
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EXPOSURE OF EARLY TRAINEES TO BONE MARROW TRANSPLANT
LEADS TO HIGHER BMT PHYSICIAN RECRUITMENT
Shereck, E.1, Shenoy, S.2, Pulsipher, M.A.3, Burns, L.4, Bracey, A.5,
Chell, J.6, Snyder, E.7, Nemecek, E.1 1Oregon Health & Science Univer-
sity, Portland, OR; 2Washington University School of Medicine, St. Louis,
MO; 3University of Utah, Salt Lake City, UT; 4University of Minnesota,
Minneapolis, MN; 5University of Texas-Houston, Houston, TX; 6Na-
tional Marrow Donor Program, Minneapolis, MN; 7Yale School of Med-
icine, New Haven, CT
The National Marrow Donor Program (NMDP) projects the
need for allogeneic unrelated blood and marrow transplants
(BMT) in the United States is 10,000 per year. While the
NMDP is preparing to facilitate that number by 2015, there are
a number of barriers to meeting this need including recruiting ad-
ditional health care personnel including BMT providers. To learn
how best to recruit BMT physicians, we sought to understand why
practicing BMT physicians chose to enter BMT, and why others
did not. We conducted a web-based survey amongst Pediatric He-
matology/Oncology (PHO) and BMT physician providers and
trainees to determine the factors influencing their decision to
choose or not choose a career in BMT. There were 259 respon-
dents (48% male, 74% of Caucasian origin); 94 identified as
BMT physicians, 112 as PHO physicians and 53 as PHO trainees.
PHO and BMT providers spent an average of 53% in clinical
S312 Poster Session Iactivities. More than 2/3 of PHO providers stated that they pro-
vide BMT services at their institutions, most commonly inpatient
coverage (73%). The proportion of providers exposed to BMT
early in their training was significantly higher amongst BMT pro-
viders than PHO providers (51% vs. 18% during medical school
[p\0.0001] and 70% vs. 50% during residency [p\ 0.005]). Ex-
posure during fellowship (94%) did not differ amongst groups.
The decision to pursue a career in BMT was made before fellow-
ship (medical school or residency) in 50% of the respondents. A
lower proportion of BMT providers reported currently being in-
volved in education of medical students and residents compared
to PHO providers (98% vs. 76%, p\0.0001). Of 53 trainees,
64% reported that they were not contemplating a career in
BMT. Of these, 68% stated that inadequate exposure to BMT
prior to PHO fellowship was the reason. Only 26% reported
BMT exposure in medical school and 43% during residency.
The two most common reasons for the choice of a BMT career
were the degree of intellectual and scientific challenge (89%)
and role models/mentors in the field (67%). This survey suggests
that early exposure to BMT during medical school and residency
results in increased interest in pursuing a career in BMT. BMT
physicians and training program directors can foster interest in
the BMT field by promoting BMT focused education and clinical
inpatient and outpatient rotations during medical school and res-
idency. This early exposure to BMT may aid in a higher recruit-
ment of future transplant providers.289
HIGH DOSE METHYLPREDNISOLONE FOR VENO-OCCLUSIVE DISEASE OF
THE LIVER IN PEDIATRIC BONE MARROW TRANSPLANT RECIPIENTS
Myers, K.C.1, Bleesing, J.J.1, Filipovich, A.H.1, Marsh, R.A.1,
Jordan, M.B.1, Kumar, A.1, Grimley, M.S.1, Lawrence, J.M.2,
Mehta, P.A.1, Davies, S.M.1, Jodele, S.1 1Cincinnati Children’s Hospital
Medical Center, Cincinnati, OH; 2Cincinnati Children’s HospitalMedical
Center, Cincinnati, OH
Veno-occlusive disease (VOD) of the liver is a well-recognized se-
rious complication of stem cell transplantation (SCT) with very few
successful treatment modalities available for severe disease. While
there have been some reports demonstrating success in adults with
high dose steroid therapy, experience in the pediatric population is
lacking. In 587 consecutive SCT patients treated at our institution
since 2003 we retrospectively identified 14 (2.4%) who developed
VOD.Of these 8 (57%) were treated with high-doseMethylprednis-
olone (500 mg/m2/dose every 12 hours for 6 doses). Steroid therapy
was initiated at or prior to first ultrasound evidence of reversal of
portal venous flow, and prior to meeting criteria for initiation of de-
fibrotide therapy. Four of these patients were also treated with De-
fibrotide starting 2 to 5 days following initiation of steroids. Seven
patients with VOD were diagnosed with multi-organ failure
(MOF) due to renal impairment and pulmonary dysfunction attrib-
utable to fluid overload or mechanical impingement from abdominal
distention or hepatic enlargement. Four of these 7 patients required
renal replacement therapy (RRT) and 5 required ventilator support
(see Table). Response to high dose steroid therapy as defined by de-
crease in bilirubin by 50% by ten days from therapy initiation wasTable.
Patient / Dgn Donor (match) Age (years) Portal System Doppler Days
1 / PPB Auto 7 Reversal of Flow
2 / CGD URD (7/8) 10.6 Reversal of Flow
3 / RB Auto 0.7 Reversal of Flow
4 / ALL MSD (8/8) 16.2 Reversal of Flow
5 / FA MUD (8/8) 6.3 Reversal of Flow
6 / NB Auto 6.6 Reversal of Flow
7 / ALL MUD (8/8) 4.8 Reversal of Flow
8 / DKC MSD (8/8) 1.2 Reversal of Flow
BMT indicates bone marrow transplant; DKC, dyskeratosis congenita; MSD, m
tologous stem cell transplant; ALL, acute lymphoblastic leukemia; MUD, matche
ulomatous disease; URD, unrelated donor; **RRTand ventilator support, *vennoted in 5/8 (63%) patients, occurring within 3 and 6 days of steroid
therapy. Two patients died due to VODwithMOF. Six survivors re-
covered from VOD at the median 15d (range 4-40) from VOD diag-
nosis. Overall survival as a groupwas 75%; however survival amongst
responders was 100%. No serious toxicities related to high dose ste-
roid therapy, such as refractory hypertension, increased infection, or
behavioral disturbances were observed. Transient hyperglycemia
was seen in some patients. We conclude that high dose steroid ther-
apy if initiated early may reverse VOD of the liver in pediatric SCT
patients, abrogating the need for defibrotide therapy with its associ-
ated toxicities and regulatory difficulties. Further prospective clinical
trials are required to assess the true efficacy of high dose steroid ther-
apy for post SCT VOD.290
BONE HEALTH IN CHILDREN AND ADOLESCENTS UNDERGOING HEMA-
TOPOIETIC CELL TRANSPLANTATION IN A SINGAPORE CENTER
Goh, Z.3, Low, S.L.2, Khanlian, C.1, Mohamed Ismail, N.D.B.2,
Chua, H.C.1, Villegas, M.S.1, Lee, Y.S.1, Tan, P.L.1 1National Univer-
sity Health System, Singapore; 2National University Health System, Sin-
gapore; 3Yong Loo Lin School of Medicine, National University of
Singapore, Singapore
We retrospectively reviewed 103 pediatric patients transplanted
between 2001-2010 to evaluate the prevalence of low bone mineral
density (BMD). Areal BMD of the lumbar spine and whole body
were determined by dual energy X-ray absorptiometry (DXA) im-
aging. Z-scores calculated were standardized by age and gender
based on a reference population. BMD was defined as normal if
Z-score . -1.0; borderline low if -2.0 \ Z-score # -1.0; low if
Z-score # -2.0; and osteoporosis if Z-score # -2.0 with a history
of fracture. Spine Z-scores were used in analysis. Only 45 of the
103 patients had any BMD records. Of these, 18 had serial
BMD evaluations. The median age at time of hematopoietic cell
transplant (HCT) was 10.2 (range, 0.1-16.8) years. Forty-three pa-
tients had allogeneic (4 had 2 HCT) while 2 had autologous HCT.
Majority (N 5 30) received non-radiation based preparative regi-
men; the commonest indication being a hematologic malignancy
(N 5 33). Majority (N 5 33) had graft versus host disease; 27 of
whom required systemic steroids. Of the patients who had pre
HCT BMD, 45% (5 of 11) already had abnormal Z-scores. Trend-
ing of BMD was possible in 17 of the 45 patients who had more
than one BMD. Recovery from a nadir Z-score was noted in
40% (7 of 17) of these patients at the time of analysis. Of the pa-
tients who had post HCT BMD, 23% (9 of 39) and 28% (11 of 39)
had borderline low and low Z-scores, respectively. One of these 20
patients (5%) had clinically significant fractures fulfilling the
WHO criteria for osteoporosis. Musculoskeletal pains were re-
ported by 29% (13 of 45) of patients but an abnormal Z-score
was noted in only 60% (8 of 13). Endocrinopathies including sex
hormones and thyroid function deficiencies was noted in 13% (6
of 45) of patients. The 3 patients with hypogonadism also had ab-
normal BMD and required hormonal replacement. One of these 3
patients received an oral bisphosphonates. Majority had calcium/
vitamin D supplements and about half (19 of 45) had physiother-
apy to optimize bone health. Despite the limitations known offrom BMT to VOD Therapy Multiorgan Failure Status
+31 Steroids Yes Alive
+11 Steroids No Alive
+14 Steroids Yes* Alive
+16 Steroids/Defibrotide Yes** Alive
+15 Steroids/Defibrotide Yes** Dead
+13 Steroids/Defibrotide Yes** Alive
+12 Steroids Yes Alive
+5 Steroids/Defibrotide Yes** Dead
atched sibling donor; NB, neuroblastoma; RB, retinoblastoma; Auto, au-
d unrelated donor; PPB, pleuropulmonary blastoma; CGD, chronic gran-
tilator support.
